Literature DB >> 17015493

The natural history of juvenile or subacute GM2 gangliosidosis: 21 new cases and literature review of 134 previously reported.

Gustavo H B Maegawa1, Tracy Stockley, Michael Tropak, Brenda Banwell, Susan Blaser, Fernando Kok, Roberto Giugliani, Don Mahuran, Joe T R Clarke.   

Abstract

OBJECTIVE: Juvenile GM2 gangliosidosis is a group of inherited neurodegenerative diseases caused by deficiency of lysosomal beta-hexosaminidase resulting in GM2 ganglioside accumulation in brain. The purpose of this study was to delineate the natural history of the condition and identify genotype-phenotype correlations that might be helpful in predicting the course of the disease in individual patients.
METHODS: A cohort of 21 patients with juvenile GM2 gangliosidosis, 15 with the Tay-Sachs variant and 6 with the Sandhoff variant, was studied prospectively in 2 centers. Our experience was compared with previously published reports on 134 patients. Information about clinical features, beta-hexosaminidase enzyme activity, and mutation analysis was collected.
RESULTS: In our cohort of patients, the mean (+/-SD) age of onset of symptoms was 5.3 +/- 4.1 years, with a mean follow-up time of 8.4 years. The most common symptoms at onset were gait disturbances (66.7%), incoordination (52.4%), speech problems (28.6%), and developmental delay (28.6%). The age of onset of gait disturbances was 7.1 +/- 5.6 years. The mean time for progression to becoming wheelchair-bound was 6.2 +/- 5.5 years. The mean age of onset of speech problems was 7.0 +/- 5.6 years, with a mean time of progression to anarthria of 5.6 +/- 5.3 years. Muscle wasting (10.6 +/- 7.4 years), proximal weakness (11.1 +/- 7.7 years), and incontinence of sphincters (14.6 +/- 9.7 years) appeared later in the course of the disease. Psychiatric disturbances and neuropathy were more prevalent in patients with the Sandhoff variant than in those with the Tay-Sachs variant. However, dysphagia, sphincter incontinence, and sleep problems occurred earlier in those with the Tay-Sachs variant. Cerebellar atrophy was the most common finding on brain MRI (52.9%). The median survival time among the studied and reviewed patients was 14.5 years. The genotype-phenotype correlation revealed that in patients with the Tay-Sachs variant, the presence of R178H and R499H mutations was predictive of an early onset and rapidly progressive course. The presence of either G269S or W474C mutations was associated with a later onset of symptoms along with a more slowly progressive disease course.
CONCLUSIONS: Juvenile GM2 gangliosidosis is clinically heterogeneous, not only in terms of age of onset and clinical features but also with regard to the course of the disease. In general, the earlier the onset of symptoms, the more rapidly the disease progresses. The Tay-Sachs and Sandhoff variants differed somewhat in the frequency of specific clinical characteristics. Speech deterioration progressed more rapidly than gait abnormalities in both the Tay-Sachs variant and Sandhoff variant groups. Among patients with the Tay-Sachs variant, the HEXA genotype showed a significant correlation with the clinical course.

Entities:  

Mesh:

Year:  2006        PMID: 17015493      PMCID: PMC2910078          DOI: 10.1542/peds.2006-0588

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  97 in total

1.  A new N-acetyl-beta-D-hexosaminidase disease with late onset of progressive neurological symptoms.

Authors:  M A Chester; B Hultberg; H Liedholm; P A Ockerman
Journal:  Hum Hered       Date:  1979       Impact factor: 0.444

2.  An atypical form of Sandhoff's disease. Case report and biochemical studies.

Authors:  I Felding; B Hultberg
Journal:  Neuropadiatrie       Date:  1978-02

3.  Adult GM2 gangliosidosis in association with Tay-Sachs disease: a new phenotype.

Authors:  R Navon; Z Argov; N Brand; U Sandbank
Journal:  Neurology       Date:  1981-11       Impact factor: 9.910

4.  Juvenile spinal muscular atrophy: a new hexosaminidase deficiency phenotype.

Authors:  W G Johnson; H J Wigger; H R Karp; L M Glaubiger; L P Rowland
Journal:  Ann Neurol       Date:  1982-01       Impact factor: 10.422

5.  Juvenile progressive dystonia: a new phenotype of GM2 gangliosidosis.

Authors:  D Meek; L S Wolfe; E Andermann; F Andermann
Journal:  Ann Neurol       Date:  1984-04       Impact factor: 10.422

6.  The AB-variant of GM2-gangliosidosis. Clinical, biochemical, and pathological studies of two patients.

Authors:  J E Goldman; T Yamanaka; I Rapin; M Adachi; K Suzuki; K Suzuki
Journal:  Acta Neuropathol       Date:  1980       Impact factor: 17.088

7.  Juvenile GM2 gangliosidosis (AMB variant): inability to activate hexosaminidase A by activator protein.

Authors:  K Inui; E E Grebner; L G Jackson; D A Wenger
Journal:  Am J Hum Genet       Date:  1983-07       Impact factor: 11.025

8.  Juvenile Sandhoff Disease: complementation tests with Sandhoff and Tay-Sachs disease using polyethylene glycol-induced cell fusion.

Authors:  S Wood
Journal:  Hum Genet       Date:  1978-04-24       Impact factor: 4.132

9.  Alpha-locus hexosaminidase genetic compound with juvenile gangliosidosis phenotype: clinical, genetic, and biochemical studies.

Authors:  W G Johnson; C S Cohen; A F Miranda; S P Waran; A M Chutorian
Journal:  Am J Hum Genet       Date:  1980-07       Impact factor: 11.025

10.  Chronic GM2 gangliosidosis masquerading as atypical Friedreich ataxia: clinical, morphologic, and biochemical studies of nine cases.

Authors:  J P Willner; G A Grabowski; R E Gordon; A N Bender; R J Desnick
Journal:  Neurology       Date:  1981-07       Impact factor: 9.910

View more
  48 in total

1.  An open-label Phase I/II clinical trial of pyrimethamine for the treatment of patients affected with chronic GM2 gangliosidosis (Tay-Sachs or Sandhoff variants).

Authors:  Joe T R Clarke; Don J Mahuran; Swati Sathe; Edwin H Kolodny; Brigitte A Rigat; Julian A Raiman; Michael B Tropak
Journal:  Mol Genet Metab       Date:  2010-09-17       Impact factor: 4.797

2.  Clinical, biochemical and mutation profile in Indian patients with Sandhoff disease.

Authors:  Parag M Tamhankar; Mehul Mistri; Pratima Kondurkar; Daksha Sanghavi; Jayesh Sheth
Journal:  J Hum Genet       Date:  2015-11-19       Impact factor: 3.172

Review 3.  Clinical neurogenetics: neuropathic lysosomal storage disorders.

Authors:  Gregory M Pastores; Gustavo H B Maegawa
Journal:  Neurol Clin       Date:  2013-11       Impact factor: 3.806

Review 4.  Pathophysiological actions of neuropathy-related anti-ganglioside antibodies at the neuromuscular junction.

Authors:  Jaap J Plomp; Hugh J Willison
Journal:  J Physiol       Date:  2009-06-29       Impact factor: 5.182

Review 5.  Endoplasmic reticulum Ca(2+) handling in excitable cells in health and disease.

Authors:  Grace E Stutzmann; Mark P Mattson
Journal:  Pharmacol Rev       Date:  2011-07-07       Impact factor: 25.468

6.  Paranoid delusion as lead symptom in two siblings with late-onset Tay-Sachs disease and a novel mutation in the HEXA gene.

Authors:  Claudia Stendel; Constanze Gallenmüller; Katrin Peters; Friederike Bürger; Gwendolyn Gramer; Saskia Biskup; Thomas Klopstock
Journal:  J Neurol       Date:  2015-04-11       Impact factor: 4.849

7.  Infantile Sandhoff Disease: Unusual presentation.

Authors:  C G Muralidharan; R P S Tomar
Journal:  Med J Armed Forces India       Date:  2016-02-22

Review 8.  The GM1 and GM2 Gangliosidoses: Natural History and Progress toward Therapy.

Authors:  Debra S Regier; Richard L Proia; Alessandra D'Azzo; Cynthia J Tifft
Journal:  Pediatr Endocrinol Rev       Date:  2016-06

Review 9.  Designing and implementing a longitudinal study of children with neurological, genetic or metabolic conditions: charting the territory.

Authors:  Harold Siden; Rose Steele; Rollin Brant; Susan Cadell; Betty Davies; Lynn Straatman; Kimberley Widger; Gail S Andrews
Journal:  BMC Pediatr       Date:  2010-09-20       Impact factor: 2.125

10.  Juvenile-onset motor neuron disease caused by novel mutations in β-hexosaminidase.

Authors:  Tyler Mark Pierson; Paola A Torres; Bei-Jin Zeng; Allan M Glanzman; David Adams; Richard S Finkel; Don J Mahuran; Gregory M Pastores; Gihan I Tennekoon; Edwin H Kolodny
Journal:  Mol Genet Metab       Date:  2012-11-02       Impact factor: 4.797

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.